Compare PD & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | PTGX |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.0M | 6.4B |
| IPO Year | 2019 | 2016 |
| Metric | PD | PTGX |
|---|---|---|
| Price | $9.28 | $97.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $12.63 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 2.1M | 462.9K |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | N/A |
| EPS | ★ 0.13 | 0.05 |
| Revenue | ★ $492,546,000.00 | N/A |
| Revenue This Year | $3.58 | $874.25 |
| Revenue Next Year | $2.88 | N/A |
| P/E Ratio | ★ $73.08 | $2,055.80 |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $5.70 | $49.86 |
| 52 Week High | $17.45 | $107.84 |
| Indicator | PD | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.25 | 47.17 |
| Support Level | $6.08 | $96.36 |
| Resistance Level | $16.60 | $104.85 |
| Average True Range (ATR) | 0.55 | 4.25 |
| MACD | 0.22 | -0.26 |
| Stochastic Oscillator | 65.73 | 42.59 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.